JPWO2020249577A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2020249577A5 JPWO2020249577A5 JP2021573344A JP2021573344A JPWO2020249577A5 JP WO2020249577 A5 JPWO2020249577 A5 JP WO2020249577A5 JP 2021573344 A JP2021573344 A JP 2021573344A JP 2021573344 A JP2021573344 A JP 2021573344A JP WO2020249577 A5 JPWO2020249577 A5 JP WO2020249577A5
- Authority
- JP
- Japan
- Prior art keywords
- risdipram
- pharmaceutical composition
- midazolam
- dose
- patients
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 61
- DDLIGBOFAVUZHB-UHFFFAOYSA-N midazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NC=C2CN=C1C1=CC=CC=C1F DDLIGBOFAVUZHB-UHFFFAOYSA-N 0.000 claims 54
- 229960003793 midazolam Drugs 0.000 claims 54
- 238000005303 weighing Methods 0.000 claims 25
- 230000037396 body weight Effects 0.000 claims 19
- 208000022074 proximal spinal muscular atrophy Diseases 0.000 claims 18
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 claims 15
- 102000004328 Cytochrome P-450 CYP3A Human genes 0.000 claims 14
- 108010081668 Cytochrome P-450 CYP3A Proteins 0.000 claims 14
- 239000007853 buffer solution Substances 0.000 claims 14
- 239000000758 substrate Substances 0.000 claims 14
- 229940095064 tartrate Drugs 0.000 claims 12
- 238000011260 co-administration Methods 0.000 claims 10
- 238000002560 therapeutic procedure Methods 0.000 claims 9
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 claims 8
- 229930195725 Mannitol Natural products 0.000 claims 8
- 239000000594 mannitol Substances 0.000 claims 8
- 235000010355 mannitol Nutrition 0.000 claims 8
- 229940049920 malate Drugs 0.000 claims 7
- BJEPYKJPYRNKOW-UHFFFAOYSA-N malic acid Chemical compound OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 claims 7
- 239000003085 diluting agent Substances 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- SERLAGPUMNYUCK-DCUALPFSSA-N 1-O-alpha-D-glucopyranosyl-D-mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O SERLAGPUMNYUCK-DCUALPFSSA-N 0.000 claims 4
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims 4
- 206010010904 Convulsion Diseases 0.000 claims 4
- 239000000905 isomalt Substances 0.000 claims 4
- 235000010439 isomalt Nutrition 0.000 claims 4
- HPIGCVXMBGOWTF-UHFFFAOYSA-N isomaltol Natural products CC(=O)C=1OC=CC=1O HPIGCVXMBGOWTF-UHFFFAOYSA-N 0.000 claims 4
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 claims 4
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 4
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 claims 3
- 239000004376 Sucralose Substances 0.000 claims 3
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 claims 3
- 239000000796 flavoring agent Substances 0.000 claims 3
- 235000019634 flavors Nutrition 0.000 claims 3
- 238000001990 intravenous administration Methods 0.000 claims 3
- 229940100688 oral solution Drugs 0.000 claims 3
- 150000003839 salts Chemical class 0.000 claims 3
- 235000019408 sucralose Nutrition 0.000 claims 3
- BAQAVOSOZGMPRM-QBMZZYIRSA-N sucralose Chemical compound O[C@@H]1[C@@H](O)[C@@H](Cl)[C@@H](CO)O[C@@H]1O[C@@]1(CCl)[C@@H](O)[C@H](O)[C@@H](CCl)O1 BAQAVOSOZGMPRM-QBMZZYIRSA-N 0.000 claims 3
- 235000002906 tartaric acid Nutrition 0.000 claims 3
- 239000011975 tartaric acid Substances 0.000 claims 3
- DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 claims 2
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims 2
- 235000016623 Fragaria vesca Nutrition 0.000 claims 2
- 240000009088 Fragaria x ananassa Species 0.000 claims 2
- 235000011363 Fragaria x ananassa Nutrition 0.000 claims 2
- 239000008118 PEG 6000 Substances 0.000 claims 2
- 229920002584 Polyethylene Glycol 6000 Polymers 0.000 claims 2
- 239000002253 acid Substances 0.000 claims 2
- 239000002535 acidifier Substances 0.000 claims 2
- 239000003963 antioxidant agent Substances 0.000 claims 2
- 235000006708 antioxidants Nutrition 0.000 claims 2
- 229960005070 ascorbic acid Drugs 0.000 claims 2
- 235000010323 ascorbic acid Nutrition 0.000 claims 2
- 239000011668 ascorbic acid Substances 0.000 claims 2
- MTHSVFCYNBDYFN-UHFFFAOYSA-N diethylene glycol Chemical compound OCCOCCO MTHSVFCYNBDYFN-UHFFFAOYSA-N 0.000 claims 2
- 239000002552 dosage form Substances 0.000 claims 2
- 239000003814 drug Substances 0.000 claims 2
- 235000003599 food sweetener Nutrition 0.000 claims 2
- 239000004615 ingredient Substances 0.000 claims 2
- 239000000314 lubricant Substances 0.000 claims 2
- 239000000843 powder Substances 0.000 claims 2
- 239000000932 sedative agent Substances 0.000 claims 2
- 230000001624 sedative effect Effects 0.000 claims 2
- 208000019116 sleep disease Diseases 0.000 claims 2
- 239000003381 stabilizer Substances 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- ASKZRYGFUPSJPN-UHFFFAOYSA-N 7-(4,7-diazaspiro[2.5]octan-7-yl)-2-(2,8-dimethylimidazo[1,2-b]pyridazin-6-yl)pyrido[1,2-a]pyrimidin-4-one Chemical compound CC1=CN2N=C(C=C(C)C2=N1)C1=CC(=O)N2C=C(C=CC2=N1)N1CCNC2(CC2)C1 ASKZRYGFUPSJPN-UHFFFAOYSA-N 0.000 claims 1
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 claims 1
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 claims 1
- 230000002378 acidificating effect Effects 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 239000002775 capsule Substances 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000007979 citrate buffer Substances 0.000 claims 1
- 238000004090 dissolution Methods 0.000 claims 1
- 229940079593 drug Drugs 0.000 claims 1
- 238000009472 formulation Methods 0.000 claims 1
- 239000008187 granular material Substances 0.000 claims 1
- 238000002372 labelling Methods 0.000 claims 1
- -1 malate or tartrate Chemical compound 0.000 claims 1
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical compound C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 1
- 239000000600 sorbitol Substances 0.000 claims 1
- 239000008371 vanilla flavor Substances 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19179563 | 2019-06-12 | ||
| EP19179563.2 | 2019-06-12 | ||
| PCT/EP2020/066003 WO2020249577A1 (en) | 2019-06-12 | 2020-06-10 | New treatment of sma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022536669A JP2022536669A (ja) | 2022-08-18 |
| JPWO2020249577A5 true JPWO2020249577A5 (https=) | 2023-06-16 |
| JP2022536669A5 JP2022536669A5 (https=) | 2023-06-16 |
Family
ID=66826852
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2021573344A Pending JP2022536669A (ja) | 2019-06-12 | 2020-06-10 | Ｓｍａの新規治療 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20220168307A1 (https=) |
| EP (1) | EP3982970A1 (https=) |
| JP (1) | JP2022536669A (https=) |
| CN (1) | CN113966219A (https=) |
| WO (1) | WO2020249577A1 (https=) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP4197536A1 (en) * | 2021-12-20 | 2023-06-21 | Universitat de València | Haloperidol for use in the treatment of spinal muscular atrophy |
| CN117250301B (zh) * | 2023-11-20 | 2024-02-09 | 中国医学科学院北京协和医院 | 一种定量检测人血浆中诺西那生的液相质谱联用方法 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB0130964D0 (en) | 2001-12-24 | 2002-02-13 | Special Products Ltd | Pharmaceutical composition |
| ES2761423T3 (es) | 2014-05-15 | 2020-05-19 | Hoffmann La Roche | Compuestos para tratar la atrofia muscular espinal |
| EA036399B1 (ru) | 2015-11-12 | 2020-11-06 | Ф. Хоффманн-Ля Рош Аг | Композиции для лечения спинальной мышечной атрофии |
| EP3691647A1 (en) * | 2017-10-03 | 2020-08-12 | H. Hoffnabb-La Roche Ag | New treatment of sma |
-
2020
- 2020-06-10 WO PCT/EP2020/066003 patent/WO2020249577A1/en not_active Ceased
- 2020-06-10 CN CN202080043043.1A patent/CN113966219A/zh active Pending
- 2020-06-10 EP EP20734116.5A patent/EP3982970A1/en not_active Withdrawn
- 2020-06-10 JP JP2021573344A patent/JP2022536669A/ja active Pending
-
2021
- 2021-12-10 US US17/548,352 patent/US20220168307A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| EP2785349B1 (en) | Combination treatment of cancer | |
| CZ284928B6 (cs) | Použití riluzolu pro výrobu léčiva určeného k léčení Parkinsonovy choroby a Parkinsonových syndromů | |
| CN107519159A (zh) | 复方组合物 | |
| JP6511492B2 (ja) | 女性胃不全麻痺に関係する症状の処置 | |
| SK146297A3 (en) | Composition comprising amoxycillin and clavulanic acid | |
| TW202333675A (zh) | 用於治療癌症之組合療法之用途 | |
| JP2010065060A (ja) | 心不全処置のための複合治療 | |
| IL323792A (en) | New treatment of sma | |
| CA2350857A1 (en) | The use of growth hormone secretagogues to treat systemic lupus erythematosus and inflammatory bowel disease | |
| US20230094778A1 (en) | Treatment of moderate and severe gastroparesis | |
| ES2763437T3 (es) | Composición para el tratamiento de la esterilidad | |
| NZ224497A (en) | Pharmaceutical composition comprising flunarizine | |
| CN102448466A (zh) | 伊奈骨化醇的新治疗应用 | |
| CN110869003A (zh) | 一种不含防腐剂的固体剂型氨己烯酸药物组合物 | |
| CN1279582A (zh) | 用于口服的含血清素配方及其使用方法 | |
| JP2022153651A (ja) | 高カルシウム尿症及び腎結石症の治療方法及び治療用組成物 | |
| WO1998024411A2 (en) | Method for oral administration of buspirone | |
| JPWO2020249577A5 (https=) | ||
| US20240408004A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders | |
| WO2013173803A2 (en) | Formulations of amoxicillin and clavulanate potassium and methods for using same | |
| JP2025026838A (ja) | レボケトコナゾールによる疾患の処置方法 | |
| EP3897579A1 (en) | Compositions, devices, and methods for the treatment of overdose and reward-based disorders | |
| WO2012005605A1 (en) | A combination composition comprising ibuprofen and paracetamol | |
| WO2020155507A1 (zh) | 一种不含防腐剂的固体剂型氨己烯酸药物组合物 | |
| KR20100047872A (ko) | 자궁내막증의 요법에서 요법 부작용을 동시 감소시키며 임신의 경우에 선천성 기형의 위험을 감소시키기 위한 (6ｓ)-5-메틸테트라히드로폴레이트와 조합된 게스타겐의 용도 |